Content Library

The allogeneic cell therapy space has many development and manufacturing bottlenecks which are further compounded by the diversity of cell types, delivery systems and gene editing technologies that are now being pursued in the clinic.

To better elucidate these challenges Hanson Wade Intelligence, our Market Research division, spoke to 15 key opinion leaders within the allogeneic cell therapy space. We summarised their views alongside quantitative insights from our Beacon Adoptive Cell database in this opinion review.

This report aims to provide cell therapy developers with valuable insights on the main allogeneic manufacturing challenges and considerations for optimisation of key stages of development.